Is Promethazine (Phenergan) Contraindicated in CKD Stage 3b?
Promethazine is NOT formally contraindicated in CKD stage 3b (eGFR 30-44 mL/min), but it should be used with extreme caution or avoided due to significant safety concerns in patients with renal impairment.
FDA Labeling and Formal Contraindications
The FDA drug label for Phenergan does not list renal impairment as an absolute contraindication 1. The formal contraindications are:
- Pediatric patients <2 years (respiratory depression risk)
- Intra-arterial or subcutaneous injection
- IV concentrations >1 mg/mL
- Comatose patients
- Known hypersensitivity to promethazine
Critical Safety Concerns in Renal Disease
Accumulation and Toxicity Risk
While not formally contraindicated, promethazine poses significant risks in CKD patients. A case series documented severe toxic psychosis in patients with chronic renal failure requiring hemodialysis who received promethazine, with symptoms including extreme restlessness, hallucinations, and belligerent behavior 2. Importantly, hemodialysis did not appear to clear the drug or improve the clinical course, suggesting significant drug accumulation in renal impairment.
Expert Consensus on Avoidance
A 2009 consensus guideline by geriatric clinical pharmacists, while not specifically addressing promethazine dosing in CKD, established recommendations for avoiding certain medications below specific renal function thresholds 3. The pattern of evidence suggests phenothiazines accumulate dangerously in renal failure.
Clinical Reasoning
The risk-benefit ratio strongly favors avoiding promethazine in CKD stage 3b for these reasons:
CNS toxicity: Phenothiazines accumulate in renal failure, causing severe neuropsychiatric complications that are not dialyzable 2
Respiratory depression: The FDA black box warning emphasizes respiratory depression risk, which may be amplified in patients with uremia-related altered drug metabolism 1
Poor evidence base: Recent evidence confirms promethazine lacks good evidence for its primary indication (sleep aid) and has an unacceptable side-effect profile 4
Safer alternatives exist: For nausea/vomiting or sleep disturbances, other agents with better safety profiles in renal disease should be prioritized
Practical Recommendation
If promethazine must be used in CKD stage 3b:
- Use the lowest possible dose
- Monitor closely for CNS effects (confusion, hallucinations, agitation)
- Avoid concurrent CNS depressants
- Consider alternative antiemetics (ondansetron) or sleep aids (cognitive-behavioral therapy for insomnia per NICE guidelines 4)
- Be prepared that symptoms may persist even after discontinuation
Better approach: Select alternative medications with established safety profiles in moderate-to-severe CKD rather than accepting the unpredictable toxicity risk of promethazine in this population.